Disruption of energy utilization in diabetic cardiomyopathy; a mini review.
Disruption of energy utilization in diabetic cardiomyopathy; a mini review.
Curr Opin Pharmacol. 2020 Sep 24;54:82-90
Authors: Nirengi S, Peres Valgas da Silva C, Stanford KI
Abstract
Type 2 diabetes (T2D) substantially elevates the risk for heart failure, a major cause of death. In advanced T2D, energy metabolism in the heart is disrupted; glucose metabolism is decreased, fatty acid (FA) metabolism is enhanced to maintain ATP production, and cardiac function is impaired. This condition is termed diabetic cardiomyopathy (DCM). The exact cause of DCM is still unknown although altered metabolism is an important component. While type 2 diabetes is characterized by insulin resistance, the traditional antidiabetic agents that improve insulin stimulation or sensitivity only partially improve DCM-induced cardiac dysfunction. Recently, sodium-glucose transporter-2 (SGLT2) inhibitors have been identified as potential pharmacological agents to treat DCM. This review highlights the molecular mechanisms underlying cardiac energy metabolism in DCM, and the potential effects of SGLT2 inhibitors.
PMID: 32980777 [PubMed - as supplied by publisher]
Source: Current Opinion in Pharmacology - Category: Drugs & Pharmacology Authors: Nirengi S, Peres Valgas da Silva C, Stanford KI Tags: Curr Opin Pharmacol Source Type: research
More News: Cardiology | Cardiomyopathy | Diabetes | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Heart | Heart Failure | Insulin | SGLT2 Inhibitors | Sodium